Eyluxvi is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),- visual impairment due to diabetic macular oedema (DME) (see section 5.1),- visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).
PAVBLU — AMGEN INC, approved 2026-04-28 (BLA761298).
25,247 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.